The Sera miRNA Pattern in Patients Inflammatory Bowel Disease
-
Mohammad Hossein Ghorbani
,
Vahid Chaleshi
,
Nazanin Amiri
,
Maryam Nasserinejad
,
Shaghayegh Baradaran Ghavami
,
Shabnam Shahrokh
,
Massoud Vosough
,
Hamid Asadzadeh Aghdaei
,
Mohammad Reza Zali
Abstract
Inflammatory bowel disease comprising Crohn's disease and ulcerative colitis presents with periods of flares and remission. Many reports have identified different dysregulated miRNAs in patients with IBD. Finding new biomarkers in IBD patients can help to launch a novel non-invasive approach for diagnosis and prognosis for patients with UC and CD. This study aimed to evaluate the plasma expression pattern of the miRNAs panel in IBD patients compared to healthy individuals. 73 plasma samples were included; 58 patients with IBD (33 individuals in flare and 25 in remission phase) and 15 healthy controls were enrolled in the study. The miRNA expression was measured by qRT-PCR using miScript SYBR Green PCR Kit (QIAGEN). Our results showed the expression level of miR-16-5P was significantly increased in the active phase compared to the inactive phase (P=0.0138) and in CD patients compared to UC patients (P=0.0216). There was a significant difference in the expression of miR-29a in Crohn's patients compared to healthy subjects (P=0.04). Measuring the expression of mir-106a; a significant increase was observed compared to healthy individuals (P=0.03) and patients with CD (P=0.0143) in proportion of UC patients’ group. The miR-126 expression significantly increased in patients with active disease compared to patients in the inactive phase (P=0.0413) and healthy controls (P=0.0492). This study showed evidence for differential expression levels of plasma panel of miR-16, miR-29a, miR-106a, and miR-126 in IBD patients compare to healthy individuals. We illustrate that miRNAs in plasma correlate with disease activity and can be used as a practical and non-invasive biomarker for early diagnosis and monitoring of the treatment protocol.
1. Zemach A, McDaniel IE, Silva P, Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science
2010;328(5980):916-9.
2. Liu T-C, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annual Review of Pathology: Mechanisms of Disease. 2016;11:127-48.
3. Wong K, Isaac DM, Wine E. Growth delay in inflammatory bowel diseases: significance, causes, and management. Digestive Diseases and Sciences. 2021;66(4):954-64.
4. Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomedical reports. 2017;6(6):698-702.
5. Tanaka M, Kawakami A, Iwao Y, Fukushima T, Takai Y, Yamamoto-Mitani N. The gap between flare-up recognition and judgment of need for physician visit in patients with ulcerative colitis. Gastroenterology Research. 2013;6(2):49-55.
6. Alemany-Cosme E, Sáez-González E, Moret I, Mateos B, Iborra M, Nos P, et al. Oxidative stress in the pathogenesis of crohn’s disease and the interconnection with immunological response, microbiota, external environmental factors, and epigenetics. Antioxidants. 2021;10(1):64.
7. Karimkhani S, Chaleshi V, Balaii H, Tarban P, Nourian M, Irani S, et al. Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population. Reports of Biochemistry and Molecular Biology. 2018;7(1):16-22.
8. Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Frontiers in immunology. 2015;6.
9. Liu TC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol. 2016;11:127-48.
10. Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and MicroRNAs in Cancer. International journal of molecular sciences. 2018;19(2).
11. Pajares MJ, Alemany-Cosme E, Goñi S, Bandres E, Palanca-Ballester C, Sandoval J. Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. International journal of molecular sciences. 2021;22(14):7350.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. cell. 2005;120(1):15-20.
14. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences. 2009;106(11):4402-7.
15. Jonaitis P, Kiudelis V, Streleckiene G, Gedgaudas R, Skieceviciene J, Kupcinskas J. Novel Biomarkers in the Diagnosis of Benign and Malignant Gastrointestinal Diseases. Digestive Diseases. 2022;40(1):1-13.
16. Iborra M, Bernuzzi F, Correale C, Vetrano S, Fiorino G, Beltrán B, et al. Identification of serum and tissue micro‐RNA expression profiles in different stages of inflammatory bowel disease. Clinical & Experimental Immunology. 2013;173(2):250-8.
17. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflammatory bowel diseases. 2010;16(10):1729-38.
18. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology. 2008;135(5):1624-35. e24.
19. Fasseu M, Treton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PloS one. 2010;5(10):e13160.
20. Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PloS one. 2012;7(12):e52782.
21. Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol. 2015;8(1):4-22.
22. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619-26.
23. De Oliveira NFP, Andia DC, Planello AC, Pasetto S, Marques MR, Nociti Jr FH, et al. TLR2 and TLR4 gene promoter methylation status during chronic periodontitis. Journal of clinical periodontology. 2011;38(11):975-83.
24. Kaplan G. The global burden of IBD: from 2015 to 2025. Nature reviews Gastroenterology hepatology. 2015;12(12):720-7.
25. Moein S, Vaghari-Tabari M, Qujeq D, Majidinia M, Nabavi SM, Yousefi B. MiRNAs and inflammatory bowel disease: An interesting new story. J Cell Physiol. 2019;234(4):3277-93.
26. Lu Q, Wu R, Zhao M, Garcia-Gomez A, Ballestar E. miRNAs as Therapeutic Targets in Inflammatory Disease. Trends Pharmacol Sci. 2019;40(11):853-65.
27. Lv B, Liu Z, Wang S, Liu F, Yang X, Hou J, et al. MiR-29a promotes intestinal epithelial apoptosis in ulcerative colitis by down-regulating Mcl-1. nternational journal of clinical
experimental pathology. 2014;7(12):8542.
28. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nature immunology. 2011;12(9):861.
29. Wang L-g, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer epidemiology. 2012;36(1):e61-e7.
30. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International journal of cancer. 2010;127(1):118-26.
31. Song J, Li N, Xia Y, Gao Z, Zou S-F, Yan Y-H, et al. Arctigenin confers neuroprotection against mechanical trauma injury in human neuroblastoma SH-SY5Y cells by regulating miRNA-16 and miRNA-199a expression to alleviate inflammation. Journal of Molecular Neuroscience. 2016;60(1):115-29.
32. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, et al. miRNA profiling of naive, effector and memory CD8 T cells. 2007;2(10):e1020.
33. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. 2010;16(10):1729-38.
34. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis research. 2008;10(4):R101.
35. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M. Circulating MicroRNA in inflammatory bowel disease. Journal of Crohn's & colitis. 2012;6(9):900-4.
36. Omidbakhsh A, Saeedi M, Khoshnia M, Marjani A, Hakimi S. Micro-RNAs -106a and -362-3p in Peripheral Blood of Inflammatory Bowel Disease Patients. The open biochemistry journal. 2018;12:78-86.
37. Chen T, Xue H, Lin R, Huang Z. MiR-126 impairs the intestinal barrier function via inhibiting S1PR2 mediated activation of PI3K/AKT signaling pathway. Biochemical and biophysical research communications. 2017;494(3-4):427-32.
38. Thorlacius-Ussing G, Schnack Nielsen B, Andersen V, Holmstrom K, Pedersen AE. Expression and Localization of miR-21 and miR-126 in Mucosal Tissue from Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(5):739-52.
2010;328(5980):916-9.
2. Liu T-C, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annual Review of Pathology: Mechanisms of Disease. 2016;11:127-48.
3. Wong K, Isaac DM, Wine E. Growth delay in inflammatory bowel diseases: significance, causes, and management. Digestive Diseases and Sciences. 2021;66(4):954-64.
4. Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomedical reports. 2017;6(6):698-702.
5. Tanaka M, Kawakami A, Iwao Y, Fukushima T, Takai Y, Yamamoto-Mitani N. The gap between flare-up recognition and judgment of need for physician visit in patients with ulcerative colitis. Gastroenterology Research. 2013;6(2):49-55.
6. Alemany-Cosme E, Sáez-González E, Moret I, Mateos B, Iborra M, Nos P, et al. Oxidative stress in the pathogenesis of crohn’s disease and the interconnection with immunological response, microbiota, external environmental factors, and epigenetics. Antioxidants. 2021;10(1):64.
7. Karimkhani S, Chaleshi V, Balaii H, Tarban P, Nourian M, Irani S, et al. Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population. Reports of Biochemistry and Molecular Biology. 2018;7(1):16-22.
8. Loddo I, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Frontiers in immunology. 2015;6.
9. Liu TC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol. 2016;11:127-48.
10. Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and MicroRNAs in Cancer. International journal of molecular sciences. 2018;19(2).
11. Pajares MJ, Alemany-Cosme E, Goñi S, Bandres E, Palanca-Ballester C, Sandoval J. Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. International journal of molecular sciences. 2021;22(14):7350.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. cell. 2005;120(1):15-20.
14. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences. 2009;106(11):4402-7.
15. Jonaitis P, Kiudelis V, Streleckiene G, Gedgaudas R, Skieceviciene J, Kupcinskas J. Novel Biomarkers in the Diagnosis of Benign and Malignant Gastrointestinal Diseases. Digestive Diseases. 2022;40(1):1-13.
16. Iborra M, Bernuzzi F, Correale C, Vetrano S, Fiorino G, Beltrán B, et al. Identification of serum and tissue micro‐RNA expression profiles in different stages of inflammatory bowel disease. Clinical & Experimental Immunology. 2013;173(2):250-8.
17. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. Inflammatory bowel diseases. 2010;16(10):1729-38.
18. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology. 2008;135(5):1624-35. e24.
19. Fasseu M, Treton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PloS one. 2010;5(10):e13160.
20. Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PloS one. 2012;7(12):e52782.
21. Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol. 2015;8(1):4-22.
22. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619-26.
23. De Oliveira NFP, Andia DC, Planello AC, Pasetto S, Marques MR, Nociti Jr FH, et al. TLR2 and TLR4 gene promoter methylation status during chronic periodontitis. Journal of clinical periodontology. 2011;38(11):975-83.
24. Kaplan G. The global burden of IBD: from 2015 to 2025. Nature reviews Gastroenterology hepatology. 2015;12(12):720-7.
25. Moein S, Vaghari-Tabari M, Qujeq D, Majidinia M, Nabavi SM, Yousefi B. MiRNAs and inflammatory bowel disease: An interesting new story. J Cell Physiol. 2019;234(4):3277-93.
26. Lu Q, Wu R, Zhao M, Garcia-Gomez A, Ballestar E. miRNAs as Therapeutic Targets in Inflammatory Disease. Trends Pharmacol Sci. 2019;40(11):853-65.
27. Lv B, Liu Z, Wang S, Liu F, Yang X, Hou J, et al. MiR-29a promotes intestinal epithelial apoptosis in ulcerative colitis by down-regulating Mcl-1. nternational journal of clinical
experimental pathology. 2014;7(12):8542.
28. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nature immunology. 2011;12(9):861.
29. Wang L-g, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer epidemiology. 2012;36(1):e61-e7.
30. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International journal of cancer. 2010;127(1):118-26.
31. Song J, Li N, Xia Y, Gao Z, Zou S-F, Yan Y-H, et al. Arctigenin confers neuroprotection against mechanical trauma injury in human neuroblastoma SH-SY5Y cells by regulating miRNA-16 and miRNA-199a expression to alleviate inflammation. Journal of Molecular Neuroscience. 2016;60(1):115-29.
32. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, et al. miRNA profiling of naive, effector and memory CD8 T cells. 2007;2(10):e1020.
33. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, et al. Identification of microRNAs associated with ileal and colonic Crohn's disease. 2010;16(10):1729-38.
34. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis research. 2008;10(4):R101.
35. Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M. Circulating MicroRNA in inflammatory bowel disease. Journal of Crohn's & colitis. 2012;6(9):900-4.
36. Omidbakhsh A, Saeedi M, Khoshnia M, Marjani A, Hakimi S. Micro-RNAs -106a and -362-3p in Peripheral Blood of Inflammatory Bowel Disease Patients. The open biochemistry journal. 2018;12:78-86.
37. Chen T, Xue H, Lin R, Huang Z. MiR-126 impairs the intestinal barrier function via inhibiting S1PR2 mediated activation of PI3K/AKT signaling pathway. Biochemical and biophysical research communications. 2017;494(3-4):427-32.
38. Thorlacius-Ussing G, Schnack Nielsen B, Andersen V, Holmstrom K, Pedersen AE. Expression and Localization of miR-21 and miR-126 in Mucosal Tissue from Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(5):739-52.
| Files | ||
| Issue | Vol 61 No 10 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/acta.v61i10.15659 | |
| Keywords | ||
| Inflammatory bowel disease microRNA 16 microRNA 106a microRNA 29a microRNA 126 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ghorbani MH, Chaleshi V, Amiri N, Nasserinejad M, Baradaran Ghavami S, Shahrokh S, Vosough M, Asadzadeh Aghdaei H, Zali MR. The Sera miRNA Pattern in Patients Inflammatory Bowel Disease. Acta Med Iran. 2024;61(10):599-606.
